Varigen Biosciences Corporation
Middleton, WI · Biotech · Private
Engineered fungal strains and synthetic biology platform to produce enfumafungin-like antifungal triterpenes through heterologous expression and cyclase gene swapping
varizymes.com →- Grants
- $3.5M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Novel Products for 100 Kb DNA Amplification | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · High Fidelity Linear MicroVector to Clone Complex Problematic and Large DNAs | $224,326 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel method to capture long, intact DNA for NGS applications | $280,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Repair Replicase | $399,846 | |
| Federal grant | Department of Agriculture · In The U.S., Commercial Production Of Channel Catfish (ictalurus Punctatus) Is The Leading Aquaculture Industry. However, In Recent Years The Catfish Industry Has Suffered Huge Economic Losses Due To An Epidemic Of Motile Aeromonas Septicemia (mas) Caused By A Highly Virulent Strain Of Aeromonas Hydrophila (vah). The Key To Stopping The Spread Of Infection Is The Rapid Identification Of Vah So That Containment Strategies Can Be Implemented In Time. Currently There Is Lack Offield-based Diagnosti | $171,295 | |
| Federal grant | Department of Health and Human Services · Phase I · Multi-Omics And Synbio Enabled Discovery Of Antifungal Fernene Triterpenes | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · PA-21-259, SBIR, Phase I, Rapid molecular diagnostic assay for detection of Candida auris at point of care | $252,235 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid molecular diagnostic assay for detection of Hepatitis C virus at point of care | $252,073 | |
| Federal grant | Department of Health and Human Services · Phase I · A Universal Fungal Transposase System for Increasing Natural Product and Protein Titers | $295,306 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic Biology for Splice Modulating Polyketides | $297,088 | |
| Federal grant | Department of Agriculture · ** Awards Issued Prior To January 20, 2025, Were Funded Under Previous Administrations And May Not Reflect The Priorities And Policies Of The Current Administration.** The Proposed Aqpathdx Kit Enables Rapid, Pondside Detection Of The Most Common Catfish And Tilapia Pathogens In Two Separate Panels In Less Than 30 Minutes Using A Novel Multiplex Molecular Diagnostic Assay. The Aqpathdx Kit Is Based On Multiplex Loop-mediated Isothermal Amplification (mlamp) Method, Which Allows Real-time Detecti | $649,763 | |
| Federal grant | Department of Agriculture · Objective Of This Project Is To Develop A Diagnostic Assay For Rapid Detection Of Avian Metapneumovirus (ampv) In Less Than 30 Minutes Using A Novel Multiplex Molecular Diagnostic Assay.this Diagnostic Assay Will Be Based On A Multiplex Loop-mediated Isothermal Amplification (mlamp) Method, Which Allows Real-time Detection Of Multiple Targets In A Single Reaction. This Diagnostic Test Will Be Designed To Differentiate Between Common Subtypes Of Ampv (a, B, And C) In A Single Reaction. This Assay | $174,395 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2852 | YOLO IMMUNE INC | — | — |
| 2853 | EMPHYMAB BIOTECH, LLC | — | — |
| 2854 | KSQ Therapeutics | — | $81M |
| 2855 | Varigen Biosciences Corporation | — | — |
| 2856 | Kite Pharma, Inc. | — | $79M |
| 2857 | Eyedesis Biosciences, LLC | — | — |
| 2858 | ZYMOSENSE INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.